Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 8/20 | 0.68 |
| ▸ | P4HTM | Q9NXG6 | 12/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254435 | 0.91 | VHL (0.73) | VHLP4HTMEGLN1 | |
| SCHEMBL14297830 | 0.88 | VHL (0.53) | VHLP4HTMEGLN1 | |
| SCHEMBL8255356 | 0.88 | VHL (0.71) | VHLP4HTMEGLN1 | |
| SCHEMBL8256208 | 0.84 | VHL (0.79) | VHLP4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL3595675 | 0.84 | VHL (0.78) | VHLP4HTMEGLN1 | |
| SCHEMBL8249037 | 0.83 | VHL (0.73) | VHLP4HTMEGLN1 | |
| SCHEMBL8249039 | 0.82 | VHL (0.65) | VHLP4HTMEGLN1 | |
| SCHEMBL3603539 | 0.81 | VHL (1.00) | VHLP4HTMEGLN1 | |
| SCHEMBL8254489 | 0.81 | VHL (0.71) | VHLP4HTMEGLN1 | |
| SCHEMBL8257423 | 0.81 | VHL (0.77) | VHLP4HTMEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2006114213-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | DPP7, DPP4, QDPR | VHL 38/4885P4HTM 633/4885EGLN1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.